annb0t
Top 20
ResMed (NYSE:RMD) Second Quarter 2023 Results
Key Financial Results
Revenue: US$1.03b (up 16% from 2Q 2022). Net income: US$224.9m (up 12% from 2Q 2022). Profit margin: 22% (in line with 2Q 2022). EPS: US$1.53 (up from US$1.38 in 2Q 2022). earnings-and-revenue-growth
All figures shown in the chart above are for the trailing 12 month (TTM) period
ResMed Revenues Beat Expectations
Revenue exceeded analyst estimates by 3.7%. Earnings per share (EPS) was mostly in line with analyst estimates.
...
>>> Read more: ResMed Second Quarter 2023 Earnings: Revenues Beat Expectations, EPS In Line
Key Financial Results
Revenue: US$1.03b (up 16% from 2Q 2022). Net income: US$224.9m (up 12% from 2Q 2022). Profit margin: 22% (in line with 2Q 2022). EPS: US$1.53 (up from US$1.38 in 2Q 2022). earnings-and-revenue-growth
All figures shown in the chart above are for the trailing 12 month (TTM) period
ResMed Revenues Beat Expectations
Revenue exceeded analyst estimates by 3.7%. Earnings per share (EPS) was mostly in line with analyst estimates.
...
>>> Read more: ResMed Second Quarter 2023 Earnings: Revenues Beat Expectations, EPS In Line
